Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Previously submitted to: JMIR mHealth and uHealth (no longer under consideration since May 27, 2022)

Date Submitted: Apr 14, 2022
Open Peer Review Period: Apr 14, 2022 - Jun 14, 2022
(closed for review but you can still tweet)

NOTE: This is an unreviewed Preprint

Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).

Peer review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.

Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).

Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.

Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.

Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Clinical Advice on Early Degenerative Diseases Given by Mobile Artificial Intelligence Voice Assistants: A Scope for Improvement

  • Wanbo Zhu; 
  • Xianzuo Zhang; 
  • Jiaxing Wang; 
  • Chen Zhu; 
  • Xianlong Zhang

ABSTRACT

Background:

The demand for medical advice by mobile artificial intelligence voice assistants (AI-VAs) during the ongoing COVID-19 pandemic is increasing, especially for the diagnosis and screening of seemingly insignificant degenerative diseases such as early knee osteoarthritis (KOA).

Objective:

The objective of this study is to: measure the ability of mobile AI-VA to provide responses to questions associated with KOA; identify the impact of different software, regions, and languages on such responses; and explore the accuracy of medical advice given by AI-VA when compared with those obtained through conventional methods.

Methods:

AI-VA software popular in China (such as, Huawei’s Xiaoyi and Apple’s Siri) were applied to test the responses to 15 most frequently-asked patient-centered questions associated with KOA in both the English and Chinese languages. Voice recognition and response abilities, as well as the accuracy of the medical advice given by different AI-VAs, were measured. Siri was further tested in four international medical centers with regards to the KOA questions using different languages and search engines. A questionnaire comprising the KOA questions was also sent to seven medical practitioners not specializing in KOA and five junior orthopedic surgeons as positive controls.

Results:

The speech recognition and voice response capabilities of the two aforementioned AI-VAs were similar in the Chinese language test, and Siri's accuracy of medical advice was significantly better than that of Xiaoyi's (Z=2.762, p=0.006). Siri performed much better than Xiaoyi in the English language test, especially in terms of voice response capability (53.3% vs. 0%). Siri also showed satisfactory agreement across the cities and languages tested, but there were differences in the accuracy of medical advice given by the AI-Vas when using different search engines. The accuracy of Siri's medical advice was higher than that obtained from direct web searches (95.6% vs. 53.3%, Z=4.290, p<0.001), suggesting higher ability of Siri to filter web searches. The accuracy of medical advice given by Siri was also higher than that given by clinicians not specializing in KOA and it was not found to be inferior to the medical advice given by senior orthopedic surgeons.

Conclusions:

Current performance of AI-VAs for providing voice responses is generally known to be unsatisfactory. It is limited to presenting web search results to users, and the accuracy of medical advice given by them varies between countries and search engines used. The medical advice given by AI-VAs is deemed informative only due to their ability to filter direct web search results. The diagnoses of early degenerative diseases using AI-VA is advantageous, especially during the COVID-19 pandemic which has limited users’ access to hospitals and the available medical resources are scarce. Still, mobile AI-VAs generally fail to meet expectations in the field of medicine.


 Citation

Please cite as:

Zhu W, Zhang X, Wang J, Zhu C, Zhang X

Clinical Advice on Early Degenerative Diseases Given by Mobile Artificial Intelligence Voice Assistants: A Scope for Improvement

JMIR Preprints. 14/04/2022:38763

DOI: 10.2196/preprints.38763

URL: https://preprints.jmir.org/preprint/38763

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.